Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04140396 · ClinicalTrials.gov registry record · Phase 4

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

A Phase 4 study, sponsored by Stanford University.

Terminated
Registry status
Phase 4
Development phase
1
Enrollment target

NCT04140396: Clinical Trial Phase 4 study, sponsored by Stanford University.

NCT04140396 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04140396, a Phase 4 study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
Phase 4
Development phase
1 participants
Enrollment target

Study Summary

The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of delirium. In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that IVL is overall well tolerated and have shown other beneficial effects such as anti-inflammatory properties. To this date, there have been no published randomized clinical trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture pain. Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours compared to placebo in adult patients with acute traumatic rib fractures.

Primary Outcome

MME = morphine milligram equivalent

Interventions

  • DRUG Saline infusion
  • DRUG Lidocaine infusion

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2020-02-10
Est. Completion 2020-11-09
Phase Phase 4
Stanford University

1,744 total trials

Why NCT04140396 stopped before completion

NCT04140396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 2 interventions - of which Saline infusion is the first listed.

NCT04140396 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04140396 about?

NCT04140396 is a clinical study titled "Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia". The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of deli...

What is the current status of trial NCT04140396?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2020-02-10. Estimated completion is 2020-11-09.

What interventions are being tested in trial NCT04140396?

The interventions under investigation include: Saline infusion (DRUG), Lidocaine infusion (DRUG).

Who is sponsoring clinical trial NCT04140396?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04140396's enrollment target sits among peer trials

1 2000th of 2000 the lowest of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04140396, the US trial registry maintained by the National Library of Medicine. NCT04140396 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.